Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
The immune system has a biological telecommunications system—small proteins known as interleukins that send signals among the leukocyte white blood cells to control their defense against infections or ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6). Researchers at The University of Texas ...
Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...
Immune checkpoint inhibitors have revolutionized the treatment of many cancers by using our body's immune system to kill cancer. These treatments sometimes can cause our immune system to fight healthy ...
Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine ...
A proportion of rheumatoid arthritis pain may be more appropriately considered separate from inflammation and should be treated as a focus of its own. Clinicians have long assumed that managing pain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results